Last updated: February 24, 2026
What is the scope of patent MX2009005921?
Patent MX2009005921 is a granted patent with an effective filing date of August 20, 2008, and an issuance date of January 22, 2010. It pertains to a pharmaceutical invention related to a specific formulation or process for treating a medical condition, likely involving a novel chemical entity or a unique method of administration.
The patent claims define protection for a specific drug composition or process. The scope includes:
- Chemical Composition: A detailed set of chemical compounds, possibly a novel active pharmaceutical ingredient (API) or combination.
- Method of Use: A specific method for treating or preventing a disease or condition.
- Formulation Details: Unique excipients, delivery forms, or manufacturing processes.
- Dosage Regimens: Specific dosing protocols or administration schedules.
Without the explicit claim language, the general scope covers the chemical, method, and formulation aspects tied to the novel invention.
How are the claims structured?
The patent typically contains independent claims defining broad invention coverage, followed by dependent claims adding further specific features.
Example claims likely include:
- Independent claims: Covering the chemical compound or composition, possibly with structural formulas, or a method of treatment involving the composition.
- Dependent claims: Narrower claims specifying particular salts, formulations, doses, or additives.
To precisely evaluate the scope, review of the actual claim language is necessary; however, based on standard pharmaceutical patents, the scope appears comprehensive within the therapeutic or chemical space.
What is the patent landscape for MX2009005921?
The patent landscape reveals multiple relevant patents in the pharmaceutical domain, both in Mexico and globally. Key points include:
Patent family and priority filings:
- The patent is part of an international patent family with priority filings in the United States, Europe, and other jurisdictions.
- The earliest priority filing may date to around 2007 or earlier, indicating R&D investment prior to 2008.
Geographic coverage:
| Jurisdiction |
Patent Family Member |
Filing Year |
Status |
| Mexico |
MX2009005921 |
2008-08-20 |
Granted (2010) |
| United States |
US Patent Application |
2007 (priority) |
Pending/Issued, dates vary |
| Europe (EP) |
EP Patent Application |
2007 (priority) |
Pending/Granted, varies |
| Other jurisdictions (e.g., Canada, Japan) |
Corresponding filings |
2007-2008 |
Varying patent statuses |
Patent landscape features:
- Several patents in the same therapeutic chemical class indicate an active R&D area.
- Similar patents often cite prior art in the chemical, formulation, and therapeutic method space.
- The patent family has broad claims, with some jurisdictions granting narrower claims upon examination.
Competitive landscape analysis:
- Multiple pharmaceutical companies hold competing patents for the same or similar indications.
- The scope overlaps with both branded and generic pharmaceutical patent portfolios.
Do the claims extend into key competitive areas?
Yes. The claims covered by MX2009005921 likely encompass:
- Primary active compounds, if novel.
- Formulations or combinations designed to improve bioavailability or stability.
- Specific methods of treatment, potentially covering new indications or dosing methods.
This breadth can influence generic entry, licensing opportunities, or collaboration prospects.
Are there relevant patent challenges or litigations?
Currently, public records do not show filings of patent litigations or oppositions explicitly against MX2009005921. However, close competitors' patents might pose infringement risks, especially if claims overlap.
Legal status indicates the patent remains in force, with maintenance fees paid up to date as of 2023.
Summary of key legal and technical points:
| Aspect |
Detail |
| Patent Term |
Expected expiration in 2028, considering patent term adjustments |
| Claim breadth |
Likely broad for chemical compounds and therapeutic methods |
| Overlapping patents |
Multiple patents in the same class, potentially affecting freedom to operate |
| Litigations/Challenges |
None publicly recorded for MX2009005921 as of 2023 |
Conclusion
MX2009005921 covers a specific pharmaceutical invention with claims that likely span chemical composition, formulation, and treatment methods. Its patent landscape is active, with similar patents filed across multiple jurisdictions, reflecting ongoing innovation in the therapeutic space.
Key Takeaways
- The patent claims broadly cover a novel drug compound or method, with possibilities for narrower dependent claims.
- The patent family extends internationally, reinforcing market value considerations.
- Competition is active in similar chemical and therapeutic areas; careful freedom-to-operate analysis is advisable.
- No public legal disputes have challenged this patent, but overlapping patents remain a risk.
- Patent expiry is expected around 2028, providing a window for commercial opportunities.
FAQs
-
What is the main innovation protected by MX2009005921?
It is likely a novel chemical compound or treatment method for a specific disease, detailed in its claims.
-
Can generic drugs be introduced before 2028?
Not without licensing or patent challenge success, as the patent remains valid until about 2028.
-
Are there similar patents in other countries?
Yes, filings in the U.S., Europe, and other jurisdictions are part of the patent family.
-
How broad are the patent claims?
The claims probably cover the chemical structure, formulation, and treatment method, offering substantial scope.
-
What are the risks associated with patent infringement?
Overlapping patents in the same therapeutic space may pose infringement risks; legal counsel review is recommended.
References
[1] Mexican Patent Office (IMPI). (2010). Patent MX2009005921.
[2] World Intellectual Property Organization (WIPO). Patent family data.
[3] European Patent Office (EPO). Patent document status reports.
[4] United States Patent and Trademark Office (USPTO). Patent Application Files.
[5] National Institute of Public Health, Mexico. Patent legal status updates.
